期刊
DIABETES OBESITY & METABOLISM
卷 19, 期 11, 页码 1630-1634出版社
WILEY
DOI: 10.1111/dom.12973
关键词
insulin therapy; non-alcoholic fatty liver disease
资金
- Eli Lilly and Company [NCT01481779, NCT01435616, NCT01454284, NCT01582451]
We investigated non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes (T1D), and in insulin-naive and insulin-treated patients with type 2 diabetes (T2D). Baseline data from patients who had liver fat content (LFC) evaluated by magnetic resonance imaging in four phase 3 studies of basal insulin peglispro (BIL) were analysed. Associations of NAFLD with clinical characteristics, glycaemic control and diabetes therapy were evaluated. The prevalence of NAFLD (defined as LFC >= 6%) was low in T1D (8.8%) but high in T2D, with greater prevalence in insulin-naive (75.6%) vs insulin-treated (61.7%) T2D patients. LFC (mean +/- SD) was higher in T2D patients (insulin-naive, 13.0% +/- 8.4%; insulin-treated, 10.2% +/- 7.8%) than in T1D patients (3.2% +/- 3.2%). In T2D, NAFLD was associated with several markers of insulin resistance. In all three populations, there was an absence of association of HbA1c with LFC, but insulin doses were higher in patients with NAFLD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据